Loading
Life sciences · Journal article
Medical Oncology · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Gallic acid (GA) is a plant-derived polyphenol with recognized anticancer activity, but in vivo evidence, especially in mesenchymal solid tumors, remains limited. This study investigated the antitumor effects and mechanistic pathways of GA in the murine Sarcoma 180 (S-180) model. Fifty male Swiss mice bearing S-180 tumors received oral GA (10, 25, or 50 mg/kg/day), 5-fluorouracil (5-FU; 25 mg/kg, intraperitoneal), or vehicle for seven days. Tumor weight and growth inhibition were assessed, along with histopathology and immunohistochemistry for proliferation (Ki-67, a proliferation marker), apoptosis (cleaved caspase-3 and caspase-8, Bcl-2-associated X protein [Bax], and B-cell lymphoma 2 [Bcl-2]), nuclear factor kappa B (NF-κB), and systemic toxicity markers (hematological, hepatic, and renal). GA at 50 mg/kg significantly reduced tumor weight and proliferation, decreased Ki-67 and NF-κB expression, increased Bax, reduced Bcl-2, and enhanced cleaved caspase-3, indicating predominant activation of the intrinsic (mitochondrial) apoptotic pathway. Caspase-8 levels remained unchanged. Although 5-FU produced greater tumor inhibition, it induced leukopenia and splenic atrophy, whereas GA preserved hematological, hepatic, and renal parameters. These findings support GA as a promising candidate for adjuvant cancer therapy.